Skip to main content

Biogen to buy early-stage potential Alzheimer's, Parkinson's treatment from Pfizer

By Reuters  
   January 14, 2020

Biogen Inc said on Monday it has agreed to buy an early-stage experimental treatment from Pfizer Inc that it aims to test in patients with Alzheimer’s and Parkinson’s disease. Under the deal, Pfizer will get $75 million upfront and will be eligible for $635 million in potential milestone payments.

Full story

Get the latest on healthcare leadership in your inbox.